二芳基甲基哌嗪化合物药理活性研究进展
|
摘要
具有二芳基甲基哌嗪的化合物具有广泛的药理活性,包括抗组胺、抗肿瘤、抗高血压、抗偏头痛等,通过整理文献,本文对近年来发表的二芳基甲基哌嗪化合物的药理活性研究文献进行整理和分析,为深入开展以含有二芳基甲基哌嗪结构为创新新药研究提供信息。
The structural fragment of Diarylmethyl Piperazine derivatives have multiple pharmacological activities, including antihistaminie, antitumor, antihypersive, antimigraine and so on. This article summarizes and analyzes the study literatures on the pharmacological activity of diarylmethyl piperazine derivatives published in recent years so as to provide information for studies on new drugs of diarylmethyl piperazine derivatives on the basis of the pharmacological activity.
The structural fragment of Diarylmethyl Piperazine derivatives have multiple pharmacological activities, including antihistaminie, antitumor, antihypersive, antimigraine and so on. This article summarizes and analyzes the study literatures on the pharmacological activity of diarylmethyl piperazine derivatives published in recent years so as to provide information for studies on new drugs of diarylmethyl piperazine derivatives on the basis of the pharmacological activity.
引文
[1]朱国东,陆涛.二苯基哌嗪(啶)类化合物的药理作用及研究进展[J].药学进展,2004,28(9):395-400.
[2]陶文伟.二芳基甲烷类化合物的合成及其在抗变态药物中的应用[D].杭州:浙江工业大学,2006.
[3]王天文.哌嗪类化合物的合成及其抗过敏活性研究[D].南宁:广西大学,2008.
[4]李荣东,朱志宏,段立新.盐酸西替利嗪的合成[J].中国药物化学杂志,2000,10(1):66-67,78.
[5]Reiter J,Trinka P,Bartha FL,et al.New Manufacturing Procedure of Cetirizine[J].Organic Process Research&Development,2012,16(7):1279-1282.
[6]Nutalapati,Siva RK.Methods of administering combinations of antihistamines for treatment of allergic reactions:US,20130053399[P].2013-02-28.
[7]赵增任,唐巍,杨大成,等.盐酸美克洛嗪的合成[J].中国新药杂志,2008,17(13):1138-1139,1144.
[8]杜翔宇,王晰婷,孙海龙,等.盐酸乙氟利嗪的合成[J].中国医药工业杂志.2011,42(5):321-323.
[9]Venkat NA,Narsimha P.Efficient synthesis of antihistamines clocinizine and chlorcyclizine[J].Medicinal Chemistry Research,2012,21(4):538-541.
[10]刘翔,刘庭辉,刘百里.奥沙米特合成工艺的研究[J].沈阳药科大学学报,2001,18(5):327-328.
[11]刘莹,郑腾飞,金凤,等.非肽类SARS冠状病毒3CL蛋白酶抑制剂的设计与活性表征[J].化学学报,2007,65(16):1707-1712.
[12]钟敏,彭小海,罗谨,等.盐酸羟嗪合成的研究新进展[J].化学与生物工程,2011,28(8):1-4.
[13]Brennan AB,Long CJ,Bagan JW,et al.Surface topographies for non-toxic bioadhesion control:US,20100226943[P].2010-09-09.
[14]王立升,李敬芬,周天明,等.氟桂利嗪的合成工艺研究[J].中国医药工业杂志,1997,28(10):438-440.
[15]Yeap YY,Trevaskis NL,Quach T,et al.Intestinal Bile Secretion Promotes Drug Absorption from Lipid Colloidal Phases via Induction of Supersaturation[J].Molecular Pharmaceutics,2013,10(5):1874-1889.
[16]陈汝红,王熳,刘松雁,等.双苯氟嗪中杂质的结构分析[J].中国医药药学杂志,2011,31(5):1241-1244.
[17]Moriuchi K.,Takeda Y.Binder composition for electrodes and electrode mix slurry:WO,2010100945[P].2010-09-10.
[18]肖方青,刘旭桃,郑正春,等.盐酸马尼地平的合成[J].中国医药工业杂志,2004,35(2):65-66.
[19]黄震华.新型钙通道拮抗剂马尼地平[J].中国新药与临床杂志,2003,22(4):241-244.
[20]Ott C,Schneider MP,Raff U,et al.Effects of manidipine vs.amlodipine on intrarenal haemodynamics in patients with arterial hypertension[J].British Journal of Clinical Pharmacolog,2013,75(1):129-135.
[21]葛泽梅,郭保国,王红宇,等.1-[二-(4-氟苯)甲基]-4-取代哌嗪类化合物的合成及抗肿瘤活性[J].北京大学学报:医学版,2001,33(3):213-216.
[22]Sumizawa T,Chen ZS,Chuman Y,et al.Reversal of multidrug resistance-associated protein-mediated drug resistance by the pyridine analog PAK-104P[J].Molecular pharmacology,1997,51(3):399-405.
[23]Zhang X,Mao H,Chen J,et al.Increased expression of micro RNA-221 inhibits PAK1 in endothelial progenitor cells and impairs its function via c-Raf/MEK/ERK pathway[J].Biochemical and Biophysical Research Communications,2013,431(3):404-408.
[24]王华,李云,尤启冬.盐酸洛美利嗪的合成工艺改进[J].中国药物化学杂志,2003,13(5):297-298.
[25]徐昌盛,陈国华,罗小川.盐酸洛美利嗪的合成[J].中国药科大学学报,2002,33(2):164-166.
[26]Evans CW,Viola HM,Ho D,et al.Nanoparticle-mediated internalisation and release of a calcium channel blocker[J].RSC Advances,2012,2(23):8587-8590.
[27]Collard J,Khorkova SO,Hsiao JH.Treatment of diseases related to alpha subunits of voltage-gated sodium channels(SCNx A)with small molecules[P].WO 2013036403,2013-03-14.
[28]Gengo PJ,Pettit HO,O'neill SJ,et al.DPI-3290[(+)-3-((α-R)-α-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N-(3-fluorophenyl)-N-methylbenzamide].I.A mixed opioid agonist with potent antinociceptive activity[J].Journal of Pharmacology and Experimental Therapeutics.2003,307(3):1221-1226.
[29]Mannion JC,Dax SL,Woodward R,et al.Compositions and methods for treating breathing control disorders or diseases[P].WO 2012166909,2012-12-06.
[30]王娟,曹洁,陈宝元.阿米三嗪-萝巴新治疗阻塞性睡眠呼吸暂停低通气综合征的临床研究[J].中国现代医学杂志,2011,21(29):3639-3642.
[31]张宽仁,小罗伯特·W·麦克纳特,特·W·麦克纳特,等.用于减少呼吸抑制和缓减μ阿片样化合物的副作用的组合物和方法:CN,1262600A[P].2000-08-09.
[32]Sencanski M,Ivanovic MD,Vuckovic S,et al.Modeling the ligand specificμ-andδ-opioid receptor conformations[J].Journal of the Serbian Chemical Society,2011,76(9):1247-1262.
[33]Calderon SN.Nonpeptidic deltaδopioid agonists and antagonists of the diarylmethyl piperazine class:what have we learned[J].Topics in Current Chemistry,2011,299(Chemistry of Opioids):121-140.
[34]Lazzari P,Loriga G,Ruiu S,et al.Preparation of diazapolycyclic pharmaceutical compounds for treatment of opioid receptor-mediated diseases:CA,2724086[P].2011-06-18.
[35]赵钊.新型抗抑郁药物DPI-289以及API-121的合成研究[D].昆明:昆明理工大学:2011-04.
[36]徐媛媛.策划药的发展演变及检测管制分析[J].中国药房,2014,25(13):1162-1165.
[37]赵珊,王慧娟,林冰,等.左羟丙哌嗪β-环糊精包合物的处方工艺优化及鉴定[J].中国药房,2014,25(37):3496-3499.
[2]陶文伟.二芳基甲烷类化合物的合成及其在抗变态药物中的应用[D].杭州:浙江工业大学,2006.
[3]王天文.哌嗪类化合物的合成及其抗过敏活性研究[D].南宁:广西大学,2008.
[4]李荣东,朱志宏,段立新.盐酸西替利嗪的合成[J].中国药物化学杂志,2000,10(1):66-67,78.
[5]Reiter J,Trinka P,Bartha FL,et al.New Manufacturing Procedure of Cetirizine[J].Organic Process Research&Development,2012,16(7):1279-1282.
[6]Nutalapati,Siva RK.Methods of administering combinations of antihistamines for treatment of allergic reactions:US,20130053399[P].2013-02-28.
[7]赵增任,唐巍,杨大成,等.盐酸美克洛嗪的合成[J].中国新药杂志,2008,17(13):1138-1139,1144.
[8]杜翔宇,王晰婷,孙海龙,等.盐酸乙氟利嗪的合成[J].中国医药工业杂志.2011,42(5):321-323.
[9]Venkat NA,Narsimha P.Efficient synthesis of antihistamines clocinizine and chlorcyclizine[J].Medicinal Chemistry Research,2012,21(4):538-541.
[10]刘翔,刘庭辉,刘百里.奥沙米特合成工艺的研究[J].沈阳药科大学学报,2001,18(5):327-328.
[11]刘莹,郑腾飞,金凤,等.非肽类SARS冠状病毒3CL蛋白酶抑制剂的设计与活性表征[J].化学学报,2007,65(16):1707-1712.
[12]钟敏,彭小海,罗谨,等.盐酸羟嗪合成的研究新进展[J].化学与生物工程,2011,28(8):1-4.
[13]Brennan AB,Long CJ,Bagan JW,et al.Surface topographies for non-toxic bioadhesion control:US,20100226943[P].2010-09-09.
[14]王立升,李敬芬,周天明,等.氟桂利嗪的合成工艺研究[J].中国医药工业杂志,1997,28(10):438-440.
[15]Yeap YY,Trevaskis NL,Quach T,et al.Intestinal Bile Secretion Promotes Drug Absorption from Lipid Colloidal Phases via Induction of Supersaturation[J].Molecular Pharmaceutics,2013,10(5):1874-1889.
[16]陈汝红,王熳,刘松雁,等.双苯氟嗪中杂质的结构分析[J].中国医药药学杂志,2011,31(5):1241-1244.
[17]Moriuchi K.,Takeda Y.Binder composition for electrodes and electrode mix slurry:WO,2010100945[P].2010-09-10.
[18]肖方青,刘旭桃,郑正春,等.盐酸马尼地平的合成[J].中国医药工业杂志,2004,35(2):65-66.
[19]黄震华.新型钙通道拮抗剂马尼地平[J].中国新药与临床杂志,2003,22(4):241-244.
[20]Ott C,Schneider MP,Raff U,et al.Effects of manidipine vs.amlodipine on intrarenal haemodynamics in patients with arterial hypertension[J].British Journal of Clinical Pharmacolog,2013,75(1):129-135.
[21]葛泽梅,郭保国,王红宇,等.1-[二-(4-氟苯)甲基]-4-取代哌嗪类化合物的合成及抗肿瘤活性[J].北京大学学报:医学版,2001,33(3):213-216.
[22]Sumizawa T,Chen ZS,Chuman Y,et al.Reversal of multidrug resistance-associated protein-mediated drug resistance by the pyridine analog PAK-104P[J].Molecular pharmacology,1997,51(3):399-405.
[23]Zhang X,Mao H,Chen J,et al.Increased expression of micro RNA-221 inhibits PAK1 in endothelial progenitor cells and impairs its function via c-Raf/MEK/ERK pathway[J].Biochemical and Biophysical Research Communications,2013,431(3):404-408.
[24]王华,李云,尤启冬.盐酸洛美利嗪的合成工艺改进[J].中国药物化学杂志,2003,13(5):297-298.
[25]徐昌盛,陈国华,罗小川.盐酸洛美利嗪的合成[J].中国药科大学学报,2002,33(2):164-166.
[26]Evans CW,Viola HM,Ho D,et al.Nanoparticle-mediated internalisation and release of a calcium channel blocker[J].RSC Advances,2012,2(23):8587-8590.
[27]Collard J,Khorkova SO,Hsiao JH.Treatment of diseases related to alpha subunits of voltage-gated sodium channels(SCNx A)with small molecules[P].WO 2013036403,2013-03-14.
[28]Gengo PJ,Pettit HO,O'neill SJ,et al.DPI-3290[(+)-3-((α-R)-α-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N-(3-fluorophenyl)-N-methylbenzamide].I.A mixed opioid agonist with potent antinociceptive activity[J].Journal of Pharmacology and Experimental Therapeutics.2003,307(3):1221-1226.
[29]Mannion JC,Dax SL,Woodward R,et al.Compositions and methods for treating breathing control disorders or diseases[P].WO 2012166909,2012-12-06.
[30]王娟,曹洁,陈宝元.阿米三嗪-萝巴新治疗阻塞性睡眠呼吸暂停低通气综合征的临床研究[J].中国现代医学杂志,2011,21(29):3639-3642.
[31]张宽仁,小罗伯特·W·麦克纳特,特·W·麦克纳特,等.用于减少呼吸抑制和缓减μ阿片样化合物的副作用的组合物和方法:CN,1262600A[P].2000-08-09.
[32]Sencanski M,Ivanovic MD,Vuckovic S,et al.Modeling the ligand specificμ-andδ-opioid receptor conformations[J].Journal of the Serbian Chemical Society,2011,76(9):1247-1262.
[33]Calderon SN.Nonpeptidic deltaδopioid agonists and antagonists of the diarylmethyl piperazine class:what have we learned[J].Topics in Current Chemistry,2011,299(Chemistry of Opioids):121-140.
[34]Lazzari P,Loriga G,Ruiu S,et al.Preparation of diazapolycyclic pharmaceutical compounds for treatment of opioid receptor-mediated diseases:CA,2724086[P].2011-06-18.
[35]赵钊.新型抗抑郁药物DPI-289以及API-121的合成研究[D].昆明:昆明理工大学:2011-04.
[36]徐媛媛.策划药的发展演变及检测管制分析[J].中国药房,2014,25(13):1162-1165.
[37]赵珊,王慧娟,林冰,等.左羟丙哌嗪β-环糊精包合物的处方工艺优化及鉴定[J].中国药房,2014,25(37):3496-3499.